4D Molecular Therapeutics, Inc. (FDMT) vs SOPHiA GENETICS S.A. (SOPH)
A side-by-side comparison of 4D Molecular Therapeutics, Inc. and SOPHiA GENETICS S.A. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FDMT
4D Molecular Therapeutics, Inc.
$12.56HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SOPH
SOPHiA GENETICS S.A.
$7.38HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — FDMT vs SOPH
growth of $100 · dividends reinvested · last 5yFDMT -47.2% (-12.0%/yr)SOPH -51.1% (-13.3%/yr)FDMT compounded faster over this window
FDMT SOPH
FDMT vs SOPH: by the numbers
- •FDMT is the larger company ($657M vs $619M market cap).
- •Both run net losses; SOPH's is the smaller (-93.86% vs -194.74% net margin).
- •FDMT grew revenue faster over the past five years (31.93% vs 20.33% CAGR).
Metrics side by side
Valuation
| Metric | FDMT | SOPH |
|---|---|---|
| P/S ratio | 7.14 | 7.19 |
| P/B ratio | 1.61 | 7.45 |
Profitability
| Metric | FDMT | SOPH |
|---|---|---|
| Gross margin | 91.05% | 66.63% |
| Operating margin | -187.24% | -85.01% |
| Net margin | -194.74% | -93.86% |
| ROE | -43.95% | -97.31% |
| ROIC | -44.30% | -49.73% |
Growth (annualized)
| Metric | FDMT | SOPH |
|---|---|---|
| Revenue CAGR (5Y) | 31.93% | 20.33% |
| Total return CAGR (5Y) | -13.08% | -13.62% |
Frequently asked
- Which has grown faster, FDMT or SOPH?
- Over the past five years, FDMT grew revenue faster — FDMT at a 31.93% CAGR versus SOPH at 20.33%.
- How have FDMT and SOPH total returns compared?
- Over the past 5 years, FDMT delivered -13.08% and SOPH delivered -13.62% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
4D Molecular Therapeutics ROESOPHiA GENETICS ROE4D Molecular Therapeutics operating marginSOPHiA GENETICS operating margin4D Molecular Therapeutics revenue growthSOPHiA GENETICS revenue growth4D Molecular Therapeutics free cash flowSOPHiA GENETICS free cash flow
4D Molecular Therapeutics & SOPHiA GENETICS appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.